Perospirone
Perospirone
复制标题
DOI：
10.2165/00023210-200115040-00006
复制
发表时间：
2001-01-01
期刊：
影响因子：
6
通讯作者：
McClellan, K
中科院分区：
文献类型：
--
作者：
Onrust, SV;McClellan, K
螺环酮是一种治疗精神分裂症的非典型抗精神病药物。其主要作用方式是通过拮抗5-HT2A和多巴胺D-2受体。在参加II期和III期试验的精神分裂症患者中，为期8周的口服螺环酮8- 48mg /天的疗程显示出高达75%的疗效。该药起效约为2周。用标准评定量表（简短精神病学评定量表、阳性和阴性症状量表）评定，螺环酮对精神分裂症患者的阳性、阴性和一般症状有效。在145名精神分裂症患者的试验中，与氟哌啶醇2 - 12mg /天相比，螺环酮8 - 48mg /天对阴性症状更有效，对一般症状和大多数阳性症状更有效。在一项对159名患者进行的三期比较试验中，perop螺酮的疗效与莫沙帕明相似，为50 - 300mg /天。与氟哌啶醇或莫沙帕明相比，螺环酮的锥体外系症状（EPS）往往较少发生，且通常较轻。
Perospirone is an atypical antipsychotic agent for the treatment of schizophrenia. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D-2 receptors.An 8-week course of oral perospirone 8 to 48 mg/day displayed efficacy in up to 75% of patients with schizophrenia participating in phase II and phase III trials. The onset of action of the drug was about 2 weeks.Perospirone was effective against positive, negative and general symptoms in patients with schizophrenia, as assessed with standard rating scales (Brief Psychiatric Rating Scale, Positive and Negative Symptom Scale).Compared with haloperidol 2 to 12 mg/day, perospirone 8 to 48 mg/day was significantly more effective against negative symptoms and tended to be more effective against general symptoms and most positive symptoms in a trial in 145 patients with schizophrenia. Perospirone had efficacy similar to that of mosapramine 50 to 300 mg/day in a comparative phase III trial in 159 patients.Extrapyramidal symptoms (EPS) tended to occur less often and were generally milder with perospirone than with haloperidol or mosapramine.